EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study

Jingyi Wang, Yuling Zhong, Bolin Chen, Yan Xu, Li Xu, Jia Li, Fang Xu, Qianzhi Wang, Kang Li, Yi Kong, Liyu Liu, Mei Peng und 2 weitere

Lung Cancer · 2026-05 · 215 · 109369

DOI: 10.1016/j.lungcan.2026.109369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung Cancer, 2026-05. Verfasst von Jingyi Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changs…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Science and Technology Program of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although extensive-stage small cell lung cancer (ES-SCLC) is susceptible to first-line immunotherapy combined with chemotherapy (immunochemotherapy), most patients experience relapse and resistance after initial treatment. Prospective clinical trial data with a sufficient sample size to support the safety and efficacy of ICI rechallenge after progression on first-line immunochemotherapy in patients with ES-SCLC remain lacking. METHODS: This study retrospectively analyzed the clinical data of 151 patients with ES-SCLC treated with first-line immunochemotherapy at Hunan Cancer Hospital between September 2019 and April 2025. We compared the efficacy and safety between patients who received ICI rechallenge and those who did not. The assessed endpoints included the objective response rate (ORR), disease control rate (DCR), progression-free survival for ICI rechallenge or second-line chemotherapy (PFS2), overall survival (OS), and adverse events (AEs). RESULTS: The ICI rechallenge group had a higher ORR (26.0% vs. 11.8%, p = 0.043) and DCR (75.0% vs. 47.1%, p 6 months, ICI rechallenge, and receipt of third-line or above therapy were independently associated with improved outcomes. The incidence of grade ≥ 3 treatment-related adverse events (TRAEs) did not differ significantly between the two groups. In the ICI rechallenge group, immune-related adverse events (irAEs) were mostly grade 1-2. Grade ≥ 3 irAEs occurred in only 2.0% of patients. CONCLUSION: In this real-world study, ICI rechallenge significantly improved efficacy and prognosis in patients with ES-SCLC who progressed after first-line immunochemotherapy. Prospective phase III studies are warranted to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedNeoplasm StagingAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

EfficacyExtensive-stage small cell lung cancerICI rechallengeReal-world studySafety

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha 410013, China; Department of Geriatric Respiratory and Critical Car…
  • Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha 410013, China; Graduate Collaborative Training Base of Hunan Cancer…
  • Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha 410013, China.
  • Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha 410013, China. Electronic address: wulin-calf@vip.163.com.

Förderung

  • Science and Technology Program of Hunan Province

Zitieren

APA

Wang, J., Zhong, Y., Chen, B., Xu, Y., Xu, L., Li, J., Xu, F., Wang, Q., Li, K., Kong, Y., Liu, L., Peng, M., Liang, Y., & Wu, L. (2026). Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study. Lung Cancer, 215, 109369. https://doi.org/10.1016/j.lungcan.2026.109369

Vancouver

Wang J, Zhong Y, Chen B, Xu Y, Xu L, Li J, et al. Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study. Lung Cancer. 2026;215:109369. doi:10.1016/j.lungcan.2026.109369

BibTeX
@article{Wang2026,
  author = {Wang, Jingyi and Zhong, Yuling and Chen, Bolin and Xu, Yan and Xu, Li and Li, Jia and Xu, Fang and Wang, Qianzhi and Li, Kang and Kong, Yi and Liu, Liyu and Peng, Mei and Liang, Yini and Wu, Lin},
  title = {Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study},
  journal = {Lung Cancer},
  year = {2026},
  volume = {215},
  pages = {109369},
  doi = {10.1016/j.lungcan.2026.109369}
}
Kostenlos starten →